Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 8.3 CAD 1.1% Market Closed
Market Cap: 249.3m CAD

Profound Medical Corp
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Profound Medical Corp
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Other Operating Expenses
-$1k
CAGR 3-Years
96%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanalysis Scientific Corp
XTSX:NSCI
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Ondine Biomedical Inc
LSE:OBI
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Profound Medical Corp
Glance View

Market Cap
249.3m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
7.54 CAD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Other Operating Expenses?
Other Operating Expenses
-1k USD

Based on the financial report for Dec 31, 2024, Profound Medical Corp's Other Operating Expenses amounts to -1k USD.

What is Profound Medical Corp's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
84%

The average annual Other Operating Expenses growth rates for Profound Medical Corp have been 96% over the past three years , 84% over the past five years .

Back to Top